Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Questions of statins use in liver diseases are discussed. Data from clinical studies on statins safety in cardiac patients with liver diseases are presented. Features of statins use in nonalcoholic fatty liver disease, viral hepatitis C are considered separately.

About the Author

O. M. Drapkina
I.M. Sechenov First Moscow State Medical University
Russian Federation


1. Downs JR, Clearfield M, Weis S, еt al. for the AFCAPS/ TexCAPS Research Group, (1998). Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS. JAMA 2001; 279: 1615–2

2. Heart Protection Study Collaborative Group. MRC/BHR Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7–2.

3. Bertuccio P, Levi F, Lucchini F et al. Coronary heart disease and cerebrovascular disease mortality in young adults: recent trends in Europe. European Journal of Cardiovascular Prevention and Rehabilitation 2011: 18(4): 627–34.

4. Kotseva K, Wood D, Backer GD, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. European Journal of Cardiovascular Prevention and Rehabilitation 2009;16:121–37.

5. Susekov A., M. Zubarev, Deev AD etc. The main results of the Moscow study on statins (Moscow Statin Survey, MSS). Serdtse 2006; 5 (6) :324– (Сусеков А.В., Зубарева М.Ю., Деев А.Д. и др. Основ- ные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце 2006;5(6):324–).

6. Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol 2008;24(3):287–7. 7. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583–592.

7. Kashani A, Phillips CO, Foody JM et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788–797

8. Brown W. Safety of statins. Current Opinion in Lipidology 2008; 19:558–62

9. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329(2):62–.

10. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126(5):1287–2.

11. Vasudevan A., Hamirani Y., Jones P. Safety of statins: Effects on muscle and the liver. Cleveland clinic journal of medicine 2005; 72(11): 665–8.

12. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(8A):77–1C.

13. Argo C., Loria P., Caldwell S., Lonardo A. Statins in Liver Disease: A Molehill, an Iceberg, or Neither? Hepatology 2008;48:662–69. 15. Riley P, Sudarshi D, Johal M, et al. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract 2008;62(3):374–1.

14. Drapkina OM, Korneeva ON. Clinical variants metabolic syndrome. Moscow: MIA; 2011. Russian (Драпкина О.М., Корнеева О.Н. Клинические варианты метаболического синдрома. Москва: МИА; 2011).

15. Ivashkin V., Drapkina O., Ashikhmin Y. Prevalence and risk factors for non-alcoholic fatty liver disease in Russian Federation. Journal of Hepatology 2010; 52 Suppl 1: S138–13

16. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006;44(2):466–1.

17. Ekstedt M M, Franzеn L E, Mathiesen U L, et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. Journal of Hepatology 2007; 47 (1):135–4

18. Kiderman A, Ben-Dov IZ, Glikberg F, Ackerman Z. Declining frequency of liver enzyme abnormalities with statins: experience from general practice in Jerusalem. Eur J Gastroenterol Hepatol 2008;20(10):1002–.

19. Argo C.K., Loria P., Caldwell S.H., Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008;48(2):662–. 22. Horlander JC , Kwo PY , Cummings OW et al. Atorvastatin for the treatment of NASH. Gastroenterology 2001; 120: A544.

20. Kiyici M , Gulten M , Gurel S et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis . Can J Gastroenterol 2003; 17: 713–.

21. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; 174: 193–.

22. Hatzitolios A, Savopoulos C, Lazaraki G et al. Effi cacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia . Indian J Gastroenterol 2004; 23: 131–.

23. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA et al. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients . Aliment Pharmacol Ther 2006; 23: 1643–.

24. Antonopoulos S , Mikros S , Mylonopoulou M et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233—.

25. Bader T, Fazili J, Madhoun M et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008;103(6):1383–.

26. Sezaki H, Suzuki F, Akuta N et al. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009;52(1):43–.

27. Henderson LM, Patel S, Giordano TP. Statin therapy and serum transaminases among a cohort of HCVinfected veterans. Dig Dis Sci 2010;55(1):190–.

For citation:

Drapkina O.M. STATIN SAFETY REVISITED DATA. Rational Pharmacotherapy in Cardiology. 2013;9(2):143-148. (In Russ.)

Views: 409

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)